Immuno-Oncology
Accelerate Cancer Immunotherapy Drug Discovery & Development with Fast and Clinically-Relevant Assays
|
Immuno-Oncology (IO) is a class of treatment modality designed to boost the body’s natural immune defense against cancer. The IO space is currently dominated by therapeutics development programs targeting immune checkpoint modulators as these molecules hold significant promise in cancer therapy. Another key modality is modulation of Fc-mediated effector mechanisms of therapeutics antibodies including ADCC, ADCP, and CDC.
Eurofins DiscoverX offers the most comprehensive portfolio of cell lines to enable fast, effective, and clinically-relevant understanding of IO to interrogate targets, pathways, and mechanisms to empower quicker development of IO therapeutics. Ready-to-use qualified bioassays have been developed to meet the industry requirements and regulatory expectations for fast and seamless implementation for potency testing in QC lot release of for IO drugs.
Learn how you can rapidly screen and develop antibodies, small molecules, or cellular therapies such as chimeric antigen receptor T cells (CAR-T) for your IO drug discovery and development program.
|
 |
Time-to-market is critical! Accelerate your IO drug discovery & development with robust, reproducible, and physiologically-relevant IO assays.
-
Broad Coverage of Checkpoint Modulators – Industry’s most comprehensive menu of stable cell lines and ready-to-use bioassays for targets including PD-1, SIRPα, CTLA4, OX40, ICOS, and others
-
MOA-Reflective, Robust Assays – Designed for regulatory acceptance, these assays are intended to interrogate specific target biology for fast implementation for discovery, validation, and characterization
-
Ready-To-Use Bioassay Format – Highly reproducible and robust assay performance for seamless implementation in QC lot release
-
Cytotoxicity Assays – Specifically measure direct target cell death in co-cultures using relevant immune effector cells with KILR® cytotoxicity assays for ADCC, ADCP, CAR-T, T cell redirection, and adoptive T cell therapy
Specifically Measure Target Cell Death in Co-Cultures with No Donor Variability
KILR® Cytotoxicity Assays
Easy-to-use, non-radioactive, and dye-free cytotoxicity assays to specifically measure targeted cell death in a co-culture with immune effector cells. Assays are designed to detect cancer cell death for applications like ADCC, CDC, ADCP, T cell redirection and CAR-T.
Learn More
|
Successfully Develop Drugs Targeting Checkpoint Modulators from Discovery to QC Lot Releases
MOA-Reflective Functional Assays for Co-Stimulatory and Inhibitory Checkpoint Receptors
Enable screening, lead optimization, characterization, and potency assay development of small molecule and biologic drugs. Easily implement bioassays in QC lot release with a simple, homogenous protocol and get results within a day for some targets.
Learn More
|
Accelerate Development of Drugs Targeting Interleukin Receptors
Functional Assays for Human Interleukins
Cell-based assays for functional screening, characterization, QC lot release assays, and neutralizing antibody studies. Specific, rapid assays with high matrix tolerance.
Learn More
|
Customize Solutions to Meet Specific Requirements of Your Development Programs
Custom Assay Development Services
When a solution to your need is not available, trust Eurofins DiscoverX to develop stable cell lines and custom assays that deliver results to meet the requirements of your IO drug discovery and development programs.
Learn More
|
Knowledge-Based Videos
Novel Cell-Based Assays to Enable Immunotherapy Drug Development for Checkpoint Receptors.
View Video
KILR Platform for Cytotoxicity Applications.
View Video
Single Donor-Derived KILR CD16 Effector Cells for ADCC and T Cell Redirection Applications.
View Video
Webinars
Establishing Qualified Bioassays for Checkpoint Receptors to Implement in QC Lot Release: Case Studies on PD-1 and SIRPα.
Watch Webinar
Accelerate Biologics and Biosimilars Development: Case Studies Implementing Robust and Simple Potency Bioassays.
Watch Webinar.
Implementing ADCC assays in QC: When donor variability isn’t an option.
Watch Webinar
Driving Robust ADCC and T Cell Redirection with KILR® CD16 Effector Cells.
Watch Webinar.
Biologics Webinar Series
Watch Webinars
Application Notes, Case Studies, & White Papers
Automating Cell-Based Bioassay on Tecan®’s Fluent Automation Workstation: Measuring PD-1 Signaling
Review Application Note
Accelerating Immune Checkpoint Drug Discovery through Functional Cell-Based Assays.
Read the White Paper.
Case Studies for Evaluating Checkpoint Receptor Bioassays: Fit-for-Purpose Assays Intended for QC Lot Release Programs for Therapeutic Drug Candidates.
Read the Case Studies
CAR-T Cell Screening in Tumor Spheroids using Corning® Spheroid Microplates and the KILR® Cytotoxicity Assay.
Review Application Note
A Simple & Powerful Cell-Based Assay to Quantify Specific Target Cell Death by Antibody-Dependent Cellular Phagocytosis (ADCP).
Review Application Note
Accelerating Biosimilar & Biobetter Drug Development: Ready-to-Use, Cell-Based Assays for Potency and Lot Release Testing.
Read White Paper
More available here
Blogs
Employing KILR Cytotoxicity Ready-to-Use Bioassays from Screening to Lot-Release Applications
Read Blog.
Driving robust ADCC and T cell redirection with KILR® CD16 effector cells.
Read Blog.
Developing a simple antibody dependent cell-mediated cytotoxicity assay to measure target cell death.
Read Blog.
Eliminating Donor Variability in ADCC Assays – Implementation in QC Lot Release.
Read Blog.
Webinar recap: Unlocking GPCR’s for oncology.
Read Blog.
More available here